Review article: Current management of renal dysfunction in the cirrhotic patient

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 8, 2005, Pages 949-961

  Pham, P T T ^a   Pham, P C T ^a   Rastogi, A ^a   Wilkinson, A H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; CALCINEURIN INHIBITOR; CYCLOSPORIN; DOPAMINE; ENDOTHELIN A RECEPTOR ANTAGONIST; FELYPRESSIN; MISOPROSTOL; OCTREOTIDE; ORNIPRESSIN; SARALASIN; TERLIPRESSIN; VASODILATOR AGENT;

CADAVER; DISEASE COURSE; DISEASE SEVERITY; EVALUATION; HEART FUNCTION; HEPATORENAL SYNDROME; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG FUNCTION; MORTALITY; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

EARLY DIAGNOSIS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 17244377369     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02357.x     Document Type: Review

References (95)

1. UNOS OPTN. United Network for Organ Sharing and Organ Procurement Transplantation Network (UNOS OPTN) Database as of December 26, UNOS OPTN, 2003.
2. Pham PT, Pham PC, Wilkinson AH. The kidney in liver transplantation. Clin Liver Dis 2000; 4: 567-90.
3. Carego L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154: 201-5.
4. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003; 41: 269-78.
5. Guevara M. Abecasis R, Jimenez W, et al. Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study. J Hepatol 2002; 36 (Suppl. 1): 203.
6. Swan SK, Rudy DW, Lasseter KC, et al. Randomized evaluations of the effects of the effects of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000; 133: 1-9.
7. Navasa M, Follo A, Fiella X, et al. Tumor necrosis factor rand interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27: 1227-32.
8. Aguillon D, Seguin P, Malledant Y. Syndrome hepatorenal: de la physiopathologie au traitement. Ann Fr Anesth Reanim 2003; 22: 30-8.
9. Jouet P, Meyrier A, Mal F, et al. Transjugular renal biopsy in the transplant of patients with cirrhosis and renal abnormalities. Hepatology 1996; 24: 1143-7.
10. Sam R, Leehey DJ, Picken MM, et al. Transjugular renal biopsy in patients with liver disease. Am J Kidney Dis 2001; 37: 1304-7.
11. Ito H, Hattori R, Matsuda I, et al. Hepatitis B e antigen-mediated membranous glomerulonephritis. Correlation of ultrastructural changes with HbeAg in the serum and glomeruli. Lab Invest 1981; 44: 214-20.
12. Lai KN, Lai FM. Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. Kidney Int 1991; 40 (Suppl. 35): S40-5.
13. Di Belgiojoso GB, Ferrario F, Landriani N. Virus-related glomerular diseases: histological and clinical aspects. J Nephrol 2002; 15: 469-79.
14. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-5.
15. Johnson RJ, Alpers CE, Schena FP. Membranoproliferative glomerulonephritis and cryoglobulinemic glomerulonephritis. In: Feehally, J, ed. Comprehensive Clinical Nephrology. 1st edn. Philadelphia. USA: Mosby Harcourt Publishers. 2000: 25.5 (Chapter 25, Section 5).
16. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-57.
17. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Treatment of mixed cryoglobulinemia resistant to interferon-alpha with an anti-CD 20 monoclonal antibody. Blood 2003; 101: 3818-26.
18. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37: 663-76.
19. Guillevin L, Lhote F, Jarrousse B, et al. Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients. Ann Med Interne (Paris) 1992; 143 (Suppl. 1): 63-74.
20. Zuber JP, Deruaz C, Lobrinus JA, Waeber G, Bart PA. Periarteritis nodosa and hepatitis C: a fortuitous association? Schweiz Rundsch Med Prax 2003; 92: 1717-25.
21. Guillevin L, Mahr A, Cohen P, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004; 51: 482-7.
22. Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4: 943-6.
23. Keller CK, Andrassy K, Waldherr R, Ritz E. Postinfectious glomerulonephritis - is there a link to alcoholism? Q J Med 1994; 87: 97-102.
24. Sood A, Midha V, Sood N. Myoglobinuria: a cause of acute renal failure in alcoholic hepatitis. Am J Gastroenterol 2000; 95: 3669-70.
25. Pezzano M, Richard C, Lampl E, et al. Hepatic and renal toxicity of paracetamol in chronic alcoholic patient. Presse Med 1988; 17: 21-4.
26. Trunet P, Bismuth C, Masquet C, Dally S, Sarda R. Acute tubular necrosis in acute alcoholic hepatitis with cardiac beriberi. Nouv Presse Med 1979; 8: 31-3.
27. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-48.
28. Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation (Part I). Liver Transpl 2002; 8: 91-109.
29. Okumura A, Kondo K, Hirai C, et al. Nephrogenic diabetes insipidus associated with hemochromatosis. Am J Kidney Dis 2002; 40: 403-6.
30. Wu ZL, Paller MS. Iron loading enhances susceptibility to renal ischemia in rats. Ren Fail 1994; 16: 471-80.
31. Koroshi A, Babameto A. Acute renal failure during acute fatty liver of pregnancy. Nephrol Dial Transplant 2002; 17: 1110-2.
32. Flint A. Clinical report on hydro-peritoneum, based on an analysis of forty-six cases. Am J Med Sci 1863; 45: 306.
33. Gines A, Escorsell A, Gines P. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
34. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems and renal function in cirrhosis with ascites. Gastroenterology 1988; 94: 482-7.
35. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-73.
36. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
37. Platt JF, Ellis JH, Rubin JM, et al. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20: 362-9.
38. Lieberman FL. Functional renal failure in cirrhosis. Gastroenterology 1970; 58: 108-10.
39. Witte CL, Witte MH, Dumont AE. Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology 1980; 78: 1059-68.
40. Schrier RW, Arroyo V, Bernard M, et al. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
41. Epstein M. Hepatorenal syndrome: emerging perspective. Semin Nephrol 1997; 17: 563.
42. Goldstein H, Boyle JD. Spontaneous recovery from the hepatorenal syndrome. Report of four cases. N Engl J Med 1965; 272: 895-7.
43. Metz RJ, Tompkins RK. The hepatorenal syndrome. Surg Gynecol Obstet 1976; 143: 297-304.
44. Gines A, Arroyo V, Rodes J. Renal complications. In: Schiff, ER, Sorrell, MR, Maddrey, WL, eds. Schiffs Diseases of the Liver, 8th edn. Philadelphia, USA: Lippincott-Raven, 1999: 453.
45. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-10.
46. Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995; 22: 753-8.
47. Planas R, Gines P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Gastroenterology 1990; 99: 1736-44.
48. Gines P, Guevara M, De Las Heras D, Arroyo V. Review article: Albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16 (Suppl. 5): 24-31.
49. Garcia-Tsao G. Bacterial infections in cirrhosis. Can J Gastroenterol 2004; 18: 405-6.
50. Rossle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330: 165-71.
51. Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996; 25: 135-44.
52. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701-7.
53. Sanyal AJ, Genning C, Reddy KR, et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003: 124: 634-41.
54. Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-47.
55. Schroeder ET, Anderson GH, Goldman SH, et al. Effect of blockade of angiotensin II on blood pressure, renin and altesterone in cirrhosis. Kidney Int 1976; 9: 511-9.
56. Wilson JR. Dopamine in the hepatorenal syndrome. JAMA 1977; 238: 2719-20.
57. Durkin RJ, Winter SM. Reversal of hepatorenal syndrome with the combination of norepinephrine and dopamine. Crit Care Med 1995; 23: 202-4.
58. Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist (Letter). Lancet 1996; 347: 1842-3.
59. Fevery J, Van Cutsem E, Nevens F, et al. Referral of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 1990; 11: 153-8.
60. Gines A, Salmeron JM, Gines P, et al. Oral misoprostol or intravenous prostaglandin E2 does not improve renal function in patients with cirrhosis and ascites with hyponatremia or reanl failure. J Hepatol 1994; 17: 220-6.
61. Wong F, Massie D, Hsu P. et al. Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. Gastroenterology 1994; 106: 658-63.
62. Kramer L, Hori WH. Hepatorenal syndrome. Semin Nephrol 2002; 22: 290-301.
63. Kew MC, Varma RR, Sampson DJ, et al. The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver. Gut 1973; 13: 293-6.
64. Lenz K, Hortnagl H, Druml W, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Gastroenterology 1991; 101: 1060-7.
65. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
66. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine. Hepatology 1999; 30: 870-5.
67. Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-70.
68. Ganne-Carrie N, Hadengue A, Mathurin P, et al. Hepatorenal syyndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci 1996; 41: 1054-6.
69. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.
70. Mulkay JP, Louis H, Donckier V. Long-term terlipressin administration improves renal function failure in cirrhotic patients with type I hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64: 15-9.
71. Alessandria C, Venon WD, Marzano A, et al. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14: 1363-8.
72. Duhamel C, Mauillon J, Berkelmans I, et al. Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment (Letter to the Editor). Am J Gastroenterol 2000; 95: 2984-5.
73. Halimi C, Bonnard P, Bernard B. et al. Effect of terlipressin (glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicenter pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-8.
74. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.
75. Solanki P, Chawla A, Garg R. et al. Treatment of hepatorenal syndrome. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-6.
76. Duvoux C, Zanditenas D, Hezode C. et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-80.
77. Holt S, Goodier D, Marley R, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999; 353: 294-5.
78. Angeli P, Volpin R, Gerunda G, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
79. Davenport A. Is there a role for continuous renal replacement therapies in patients with liver disease and renal failure? Kidney Int 1999; 56 (S72): S62-6.
80. Gonwa TA, Mai ML, Melton MB. Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation 2001; 71: 1424-8.
81. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002; 22(S2): 20-5.
82. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.
83. Doria C, Mandala L, Smith JD, et al. Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system. Clin Transplant 2004; 18: 365-71.
84. Doria C, Mandala L, Scott VL, et al. Noncardiogenic pulmonary edema induced by a molecular adsorbent recirculating system: case report. J Artif Organs 2003; 6: 282-5.
85. Khoo AL, Tham LS, Lim GK, Lee KH. Hypoglycemia in nondiabetic patients undergoing albumin dialysis by molecular adsorbent recirculating system. Liver Transpl 2003; 9: 949-53.
86. Gulberg V, Gerbes AL. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type I - effect on survival? Z Gastroenterol 2002; 40: 823-6.
87. Gonwa TA, Klintman GB, Levy M, et al. Impact of pre-transplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361-5.
88. Koppel MH, Coburn JW, Mims MM, et al. Transplantation of cadaveric kidney from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in patients with advanced liver disease. N Engl J Med 1969; 280: 1367-71.
89. Iwatsuki S, Popovtzer MM, Corman JL, et al. Recovery from 'hepatorenal syndrome' after orthotopic liver transplantation. N Engl J Med 1973; 289: 1155-9.
90. Seu P, Wilkinson AH, Shaked A. The hepatorenal syndrome in liver transplant recipients. Am Surg 1991; 57: 806-9.
91. Gonwa TA, Wilkinson AH. Liver transplantation and renal function: results in patients with and without hepatorenal syndrome. In: Epstein, M, ed. The Kidney in Liver Disease, 4th edn. Philadelphia, USA: Hanley and Belfus, 1996: 529-42.
92. Gowa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTx) using calcineurin-based immunotherapy. Transplantation 2001; 72: 1934-9.
93. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-40.
94. UNOS OPTN. United Network for Organ Sharing and Organ Procurement Transplantation Network (UNOS OPTN) Database as of June 6. UNOS OPTN, 2003.
95. Pham PT, Pham PC, Wilkinson AH. Renal failure in the adult renal transplant recipients. In: Busuttil RW, Klintmalm GB, eds. Transplantation of the Liver, 2nd edn. Philadelphia, USA: W.B. Saunders Co. (in press).